SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-089325
Filing Date
2024-08-14
Accepted
2024-08-14 07:48:51
Documents
15
Period of Report
2024-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2421547d1_8k.htm   iXBRL 8-K 23604
2 EXHIBIT 99.1 tm2421547d1_ex99-1.htm EX-99.1 119980
6 GRAPHIC tm2421547d1_ex99-1img01.jpg GRAPHIC 12377
  Complete submission text file 0001104659-24-089325.txt   343365

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA otlk-20240814.xsd EX-101.SCH 3048
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20240814_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20240814_pre.xml EX-101.PRE 22381
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2421547d1_8k_htm.xml XML 3656
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 241204208
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)